194 related articles for article (PubMed ID: 31604924)
21. Usefulness of cytofluorometric DNA ploidy analysis in distinguishing benign cartilaginous tumors from chondrosarcomas.
Kusuzaki K; Murata H; Takeshita H; Hirata M; Hashiguchi S; Tsuji Y; Nakamura S; Ashihara T; Hirasawa Y
Mod Pathol; 1999 Sep; 12(9):863-72. PubMed ID: 10496594
[TBL] [Abstract][Full Text] [Related]
22. IDH1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract][Full Text] [Related]
23. Microenvironment alters epigenetic and gene expression profiles in Swarm rat chondrosarcoma tumors.
Hamm CA; Stevens JW; Xie H; Vanin EF; Morcuende JA; Abdulkawy H; Seftor EA; Sredni ST; Bischof JM; Wang D; Malchenko S; Bonaldo Mde F; Casavant TL; Hendrix MJ; Soares MB
BMC Cancer; 2010 Sep; 10():471. PubMed ID: 20809981
[TBL] [Abstract][Full Text] [Related]
24. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
25. Changes in p14(ARF) do not play a primary role in human chondrosarcoma tissues.
Asp J; Brantsing C; Benassi MS; Inerot S; Sangiorgi L; Picci P; Lindahl A
Int J Cancer; 2001 Sep; 93(5):703-5. PubMed ID: 11477582
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
[TBL] [Abstract][Full Text] [Related]
27. Chordoma and chondrosarcoma gene profile: implications for immunotherapy.
Schwab JH; Boland PJ; Agaram NP; Socci ND; Guo T; O'Toole GC; Wang X; Ostroumov E; Hunter CJ; Block JA; Doty S; Ferrone S; Healey JH; Antonescu CR
Cancer Immunol Immunother; 2009 Mar; 58(3):339-49. PubMed ID: 18641983
[TBL] [Abstract][Full Text] [Related]
28. Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis.
Azzi G; Velez M; Mathias-Machado MC
Curr Opin Oncol; 2014 Jul; 26(4):403-7. PubMed ID: 24867810
[TBL] [Abstract][Full Text] [Related]
29. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9.
Li J; Wang L; Liu Z; Zu C; Xing F; Yang P; Yang Y; Dang X; Wang K
Oncotarget; 2015 Sep; 6(28):26216-29. PubMed ID: 26317788
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
[TBL] [Abstract][Full Text] [Related]
32. Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro.
Schrage YM; Lam S; Jochemsen AG; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
J Cell Mol Med; 2009 Sep; 13(9A):2843-52. PubMed ID: 18624751
[TBL] [Abstract][Full Text] [Related]
33. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma.
Bovée JV; Cleton-Jansen AM; Kuipers-Dijkshoorn NJ; van den Broek LJ; Taminiau AH; Cornelisse CJ; Hogendoorn PC
Genes Chromosomes Cancer; 1999 Nov; 26(3):237-46. PubMed ID: 10502322
[TBL] [Abstract][Full Text] [Related]
34. Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution.
Abdulfatah E; Rottmann D; Morag Y; Pantanowitz L; Udager AM; Hao W; Lucas DR
Hum Pathol; 2023 Jun; 136():63-74. PubMed ID: 37019410
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of matrilin-3 not only in osteoarthritic articular cartilage but also in cartilage-forming tumors, and down-regulation of SOX9 via epidermal growth factor domain 1-dependent signaling.
Vincourt JB; Vignaud JM; Lionneton F; Sirveaux F; Kawaki H; Marchal S; Lomazzi S; Plénat F; Guillemin F; Netter P; Takigawa M; Mainard D; Magdalou J
Arthritis Rheum; 2008 Sep; 58(9):2798-808. PubMed ID: 18759284
[TBL] [Abstract][Full Text] [Related]
36. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma.
Meijer D; de Jong D; Pansuriya TC; van den Akker BE; Picci P; Szuhai K; Bovée JV
Genes Chromosomes Cancer; 2012 Oct; 51(10):899-909. PubMed ID: 22674453
[TBL] [Abstract][Full Text] [Related]
37. p53 mutations in chondrosarcoma.
Terek RM; Healey JH; Garin-Chesa P; Mak S; Huvos A; Albino AP
Diagn Mol Pathol; 1998 Feb; 7(1):51-6. PubMed ID: 9646035
[TBL] [Abstract][Full Text] [Related]
38. Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations.
Zhang H; Puviindran V; Nadesan P; Ding X; Shen L; Tang YJ; Tsushima H; Yahara Y; Ban GI; Zhang GF; Karner CM; Alman BA
J Bone Miner Res; 2022 May; 37(5):983-996. PubMed ID: 35220602
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor effects of a nonsteroidal anti-inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator-activated receptor gamma and suppressing matrix metalloproteinase-2 expression.
Higuchi T; Takeuchi A; Munesue S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Inatani H; Shimozaki S; Kato T; Aoki Y; Abe K; Taniguchi Y; Aiba H; Murakami H; Harashima A; Yamamoto Y; Tsuchiya H
Cancer Med; 2018 May; 7(5):1944-1954. PubMed ID: 29573200
[TBL] [Abstract][Full Text] [Related]
40. Low incidence of genetic alterations of the p16CDKN2a in clear cell chondrosarcoma.
Park YK; Cho CH; Chi SG; Han CS; Ushigome S; Unni KK
Int J Oncol; 2001 Oct; 19(4):749-53. PubMed ID: 11562750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
